BECLAZONE

This brand name is authorized in Cyprus, Estonia, Hong Kong SAR China, Ireland, New Zealand.

Active ingredients

The drug BECLAZONE contains one active pharmaceutical ingredient (API):

1
UNII 5B307S63B2 - BECLOMETHASONE DIPROPIONATE
 

Beclometasone is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory activity.

 
Read more about Beclometasone

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 BECLAZONE 100mg Pressurised inhalation, solution MPI, EU: SmPC Υπουργείο Υγείας (CY)
 BECLAZONE 250mg Pressurised inhalation, solution MPI, EU: SmPC Υπουργείο Υγείας (CY)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
R03BA01 Beclometasone R Respiratory system → R03 Drugs for obstructive airway diseases → R03B Other drugs for obstructive airway diseases, inhalants → R03BA Glucocorticoids
Discover more medicines within R03BA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EE Ravimiamet 1689587
HK Department of Health Drug Office 43841, 43844
IE Health Products Regulatory Authority 13926, 13952, 13967, 13978, 14091, 14111, 14122
NZ Medicines and Medical Devices Safety Authority 11203, 11204, 11205

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.